| 1 |
Dexamethasone FDA Label
|
| 2 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3447).
|
| 3 |
Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020 Jul 17. doi: 10.1056/NEJMoa2021436.
|
| 4 |
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
|
| 5 |
Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
|
| 6 |
Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
|
| 7 |
Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
|
| 8 |
ClinicalTrials.gov (NCT00248547) Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
|
| 9 |
ClinicalTrials.gov (NCT00314743) Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell Transplantation
|
| 10 |
ClinicalTrials.gov (NCT00835965) Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries
|
| 11 |
ClinicalTrials.gov (NCT02473042) Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
|
| 12 |
ClinicalTrials.gov (NCT00401011) Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
|
| 13 |
ClinicalTrials.gov (NCT01745588) Autologous Stem Cell Transplant With Pomalidomide (CC-4047) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
|
| 14 |
ClinicalTrials.gov (NCT03924791) Transforaminal Epidural Injection in Acute Sciatica
|
| 15 |
ClinicalTrials.gov (NCT00903968) Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
|
| 16 |
ClinicalTrials.gov (NCT05936086) A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
|
| 17 |
ClinicalTrials.gov (NCT02252419) Combined Effect of Dexamethasone and Paracetamol for Postoperative Sore Throat
|
| 18 |
ClinicalTrials.gov (NCT00050414) A Study of Trabectedin in Patients With Advanced Ovarian Cancer
|
| 19 |
ClinicalTrials.gov (NCT00621985) Dexamethasone Treatment of Congenital Adrenal Hyperplasia
|
| 20 |
ClinicalTrials.gov (NCT01568866) Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
|
| 21 |
ClinicalTrials.gov (NCT00609518) A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
|
| 22 |
ClinicalTrials.gov (NCT00003213) Drugs to Reduce the Side Effects of Chemotherapy
|
| 23 |
ClinicalTrials.gov (NCT01036594) Ketoconazole and Dexamethasone in Prostate Cancer
|
| 24 |
ClinicalTrials.gov (NCT05355610) Vestibular Rehabilitation With Intratympanic Drug Therapy in Meniere's Disease
|
| 25 |
ClinicalTrials.gov (NCT00335348) Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
|
| 26 |
ClinicalTrials.gov (NCT00050440) Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
|
| 27 |
ClinicalTrials.gov (NCT00479089) Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
|
| 28 |
ClinicalTrials.gov (NCT00558896) CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
|
| 29 |
ClinicalTrials.gov (NCT00732446) Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis
|
| 30 |
ClinicalTrials.gov (NCT02609997) Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens
|
| 31 |
ClinicalTrials.gov (NCT00056160) CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
|
| 32 |
ClinicalTrials.gov (NCT06039280) Comparison of Dexamethasone and N Acetylcysteine (NAC) Versus N Acetylcysteine (NAC) Alone in the Prevention of Post Embolization Syndrome in Patients With Hepatocellular Carcinoma Following Transarterial Chemoembolization.
|
| 33 |
ClinicalTrials.gov (NCT00818259) A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
|
| 34 |
ClinicalTrials.gov (NCT01478581) Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
|
| 35 |
ClinicalTrials.gov (NCT00616603) The Effects of Dexamethasone on the Duration of Sciatic Nerve Blocks
|
| 36 |
ClinicalTrials.gov (NCT03296358) Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.
|
| 37 |
ClinicalTrials.gov (NCT03473210) The Value of Amniopatch in Preterm Premature Rupture of Membranes
|
| 38 |
ClinicalTrials.gov (NCT00375791) Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
|
| 39 |
ClinicalTrials.gov (NCT01062568) The Adrenal Contribution to Androgen Production in Girls During Puberty
|
| 40 |
ClinicalTrials.gov (NCT01794520) Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
|
| 41 |
ClinicalTrials.gov (NCT01442428) Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial
|
| 42 |
ClinicalTrials.gov (NCT00801138) The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine
|
| 43 |
ClinicalTrials.gov (NCT01339260) An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
|
| 44 |
ClinicalTrials.gov (NCT00150462) Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
|
| 45 |
ClinicalTrials.gov (NCT00693433) Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
|
| 46 |
ClinicalTrials.gov (NCT00802009) Dexamethasone and Analgesic Duration After Supraclavicular Brachial Plexus Blockade
|
| 47 |
ClinicalTrials.gov (NCT01038388) A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
|
| 48 |
ClinicalTrials.gov (NCT01440582) Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
|
| 49 |
ClinicalTrials.gov (NCT06207305) A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
|
| 50 |
ClinicalTrials.gov (NCT01965353) A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
|
| 51 |
ClinicalTrials.gov (NCT01371630) Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
|
| 52 |
ClinicalTrials.gov (NCT02802163) Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
|
| 53 |
ClinicalTrials.gov (NCT02773030) A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
|
| 54 |
ClinicalTrials.gov (NCT01794507) A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
|
| 55 |
ClinicalTrials.gov (NCT01155583) Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
|
| 56 |
ClinicalTrials.gov (NCT03740334) Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
|
| 57 |
ClinicalTrials.gov (NCT00718757) Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies
|
| 58 |
ClinicalTrials.gov (NCT03702725) Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
|
| 59 |
ClinicalTrials.gov (NCT02548962) Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
|
| 60 |
ClinicalTrials.gov (NCT01962792) Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
|
| 61 |
ClinicalTrials.gov (NCT01665794) Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
| 62 |
ClinicalTrials.gov (NCT00378105) Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
|
| 63 |
ClinicalTrials.gov (NCT01497093) Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
|
| 64 |
ClinicalTrials.gov (NCT00642954) Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)
|
| 65 |
ClinicalTrials.gov (NCT01348919) Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
|
| 66 |
ClinicalTrials.gov (NCT02335983) Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
|
| 67 |
ClinicalTrials.gov (NCT02813135) European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
|
| 68 |
ClinicalTrials.gov (NCT01660750) A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
|
| 69 |
ClinicalTrials.gov (NCT01549431) Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
|
| 70 |
ClinicalTrials.gov (NCT01583283) Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
|
| 71 |
ClinicalTrials.gov (NCT01212952) Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
| 72 |
ClinicalTrials.gov (NCT00603447) Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
|
| 73 |
ClinicalTrials.gov (NCT01979276) Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
|
| 74 |
ClinicalTrials.gov (NCT00560352) Safety Study of Dasatinib With Bortezomib (Velcade) and Dexamethasone for Multiple Myeloma
|
| 75 |
ClinicalTrials.gov (NCT03472573) Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
|
| 76 |
ClinicalTrials.gov (NCT04762745) The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
|
| 77 |
ClinicalTrials.gov (NCT02352558) A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
|
| 78 |
ClinicalTrials.gov (NCT01754402) Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma
|
| 79 |
ClinicalTrials.gov (NCT02518113) A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
|
| 80 |
ClinicalTrials.gov (NCT03668860) India Dexamethasone and Betamethasone
|
| 81 |
ClinicalTrials.gov (NCT03705507) International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
|
| 82 |
ClinicalTrials.gov (NCT04353505) Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
|
| 83 |
ClinicalTrials.gov (NCT02198235) Prolonged Popliteal Fossa Nerve Blockade (Prolonged Pop)
|
| 84 |
ClinicalTrials.gov (NCT05789589) Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
|
| 85 |
ClinicalTrials.gov (NCT04766853) Verification of the Efficacy/Safety of the Intratympanic Drug Delivery for Hearing Loss
|
| 86 |
ClinicalTrials.gov (NCT00410956) Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
|
| 87 |
ClinicalTrials.gov (NCT01938729) Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
|
| 88 |
ClinicalTrials.gov (NCT03876574) Hepatic Artery Infusion Pump for NPC Liver Metastases
|
| 89 |
ClinicalTrials.gov (NCT02402543) Pre-Emptive Analgesia in Ano-Rectal Surgery
|
| 90 |
ClinicalTrials.gov (NCT00639002) A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
|
| 91 |
ClinicalTrials.gov (NCT03773107) LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma
|
| 92 |
ClinicalTrials.gov (NCT02494882) Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
|
| 93 |
ClinicalTrials.gov (NCT02343042) Selinexor and Backbone Treatments of Multiple Myeloma Patients
|
| 94 |
ClinicalTrials.gov (NCT02389543) Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
|
| 95 |
ClinicalTrials.gov (NCT04984330) Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
|
| 96 |
ClinicalTrials.gov (NCT04514029) Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
|
| 97 |
ClinicalTrials.gov (NCT00600353) Multi-day Doses in Prevention of Nausea and Emesis
|
| 98 |
ClinicalTrials.gov (NCT03237611) Low Dose Aprepitant for Patients Receiving Carboplatin
|
| 99 |
ClinicalTrials.gov (NCT04488081) I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
|
| 100 |
ClinicalTrials.gov (NCT00630565) Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
|
| 101 |
ClinicalTrials.gov (NCT03871829) Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
|
| 102 |
ClinicalTrials.gov (NCT01478048) Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
|
| 103 |
ClinicalTrials.gov (NCT03960151) Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
|
| 104 |
ClinicalTrials.gov (NCT01374217) Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
|
| 105 |
ClinicalTrials.gov (NCT00515073) Papillary Serous Carcinoma of the Endometrium
|
| 106 |
ClinicalTrials.gov (NCT03117751) Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
|
| 107 |
ClinicalTrials.gov (NCT05977998) A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
|
| 108 |
ClinicalTrials.gov (NCT00953420) Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN). U.S. National Institutes of Health.
|
| 109 |
ClinicalTrials.gov (NCT02899052) Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
|
| 110 |
ClinicalTrials.gov (NCT01518465) Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
|
| 111 |
ClinicalTrials.gov (NCT02902965) Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma
|
| 112 |
ClinicalTrials.gov (NCT02985333) Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
|
| 113 |
ClinicalTrials.gov (NCT01651039) Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
|
| 114 |
ClinicalTrials.gov (NCT03567616) A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
|
| 115 |
ClinicalTrials.gov (NCT01572480) Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
|
| 116 |
ClinicalTrials.gov (NCT02294357) Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
|
| 117 |
ClinicalTrials.gov (NCT02467010) Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance
|
| 118 |
ClinicalTrials.gov (NCT05050305) Marizomib Central Nervous System (CNS)
|
| 119 |
ClinicalTrials.gov (NCT02353468) Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
|
| 120 |
ClinicalTrials.gov (NCT00482261) A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
|
| 121 |
ClinicalTrials.gov (NCT04329325) Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
| 122 |
ClinicalTrials.gov (NCT00378209) Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
|
| 123 |
ClinicalTrials.gov (NCT01083602) Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
|
| 124 |
ClinicalTrials.gov (NCT01370408) Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
|
| 125 |
ClinicalTrials.gov (NCT04027348) Palliative Management of Inoperable Malignant Bowel Obstruction
|
| 126 |
ClinicalTrials.gov (NCT01072773) Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
|
| 127 |
ClinicalTrials.gov (NCT02986451) Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
|
| 128 |
ClinicalTrials.gov (NCT02047253) Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment
|
| 129 |
ClinicalTrials.gov (NCT00773838) Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
|
| 130 |
ClinicalTrials.gov (NCT02401529) Effect of Steroids on Post-tonsillectomy Morbidities
|
| 131 |
ClinicalTrials.gov (NCT01159574) Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma
|
| 132 |
ClinicalTrials.gov (NCT03785184) A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
|
| 133 |
ClinicalTrials.gov (NCT03478605) Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis
|
| 134 |
ClinicalTrials.gov (NCT00972959) Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy
|
| 135 |
ClinicalTrials.gov (NCT05432414) PVd Versus Vd in NDMM Patients With RI
|
| 136 |
ClinicalTrials.gov (NCT01706666) Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
|
| 137 |
ClinicalTrials.gov (NCT02224729) Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
|
| 138 |
ClinicalTrials.gov (NCT00607581) Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
|
| 139 |
ClinicalTrials.gov (NCT02176213) Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
|
| 140 |
ClinicalTrials.gov (NCT02588417) Intrathecal Dexamethasone and Labor Analgesia
|
| 141 |
ClinicalTrials.gov (NCT01965626) A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP
|
| 142 |
ClinicalTrials.gov (NCT00740415) Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
|
| 143 |
ClinicalTrials.gov (NCT01056276) Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
|
| 144 |
ClinicalTrials.gov (NCT02445872) Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
|
| 145 |
ClinicalTrials.gov (NCT02952573) Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
|
| 146 |
ClinicalTrials.gov (NCT01862315) Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
|
| 147 |
ClinicalTrials.gov (NCT05553496) Assessment of Rituximab Therapeutic Response Versus Conventional Treatment
|
| 148 |
ClinicalTrials.gov (NCT05932524) Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia
|
| 149 |
ClinicalTrials.gov (NCT03615664) The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD
|
| 150 |
ClinicalTrials.gov (NCT01867710) Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
|
| 151 |
ClinicalTrials.gov (NCT06176235) Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia
|
| 152 |
ClinicalTrials.gov (NCT01857232) Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy. U.S. National Institutes of Health.
|
| 153 |
ClinicalTrials.gov (NCT03605056) Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
|
| 154 |
ClinicalTrials.gov (NCT02525848) Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries
|
| 155 |
ClinicalTrials.gov (NCT00492999) Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
|
| 156 |
ClinicalTrials.gov (NCT00026234) Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
|
| 157 |
ClinicalTrials.gov (NCT04843579) Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
|
| 158 |
ClinicalTrials.gov (NCT05900882) SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
|
| 159 |
ClinicalTrials.gov (NCT04414475) A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
|
| 160 |
ClinicalTrials.gov (NCT05820763) Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
|
| 161 |
ClinicalTrials.gov (NCT04925193) Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
|
| 162 |
ClinicalTrials.gov (NCT05530421) Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
|
| 163 |
ClinicalTrials.gov (NCT02628704) Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
|
| 164 |
ClinicalTrials.gov (NCT02336815) Selinexor Treatment of Refractory Myeloma
|
| 165 |
ClinicalTrials.gov (NCT02484911) Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting
|
| 166 |
ClinicalTrials.gov (NCT03219710) "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
|
| 167 |
ClinicalTrials.gov (NCT04912271) Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
|
| 168 |
ClinicalTrials.gov (NCT00619359) Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
|
| 169 |
ClinicalTrials.gov (NCT03081416) "THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"
|
| 170 |
ClinicalTrials.gov (NCT03710603) Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
|
| 171 |
ClinicalTrials.gov (NCT00707083) Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
|
| 172 |
ClinicalTrials.gov (NCT00651261) Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
| 173 |
ClinicalTrials.gov (NCT05572515) A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
|
| 174 |
ClinicalTrials.gov (NCT03765541) Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
|
| 175 |
ClinicalTrials.gov (NCT02755597) A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
|
| 176 |
ClinicalTrials.gov (NCT01470131) A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
|
| 177 |
ClinicalTrials.gov (NCT00891761) A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
| 178 |
ClinicalTrials.gov (NCT04784559) Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
|
| 179 |
ClinicalTrials.gov (NCT02351622) Caffeic Acid Tablets as a Second-line Therapy for ITP
|
| 180 |
ClinicalTrials.gov (NCT00532155) A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
|
| 181 |
ClinicalTrials.gov (NCT01002248) Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
|
| 182 |
ClinicalTrials.gov (NCT04879823) Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity
|
| 183 |
ClinicalTrials.gov (NCT02516696) BiRd vs. Rd as Initial Therapy in Multiple Myeloma
|
| 184 |
ClinicalTrials.gov (NCT01208662) Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
|
| 185 |
ClinicalTrials.gov (NCT00601172) A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
|
| 186 |
ClinicalTrials.gov (NCT04832880) Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)
|
| 187 |
ClinicalTrials.gov (NCT02362165) CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
|
| 188 |
ClinicalTrials.gov (NCT01080391) Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma
|
| 189 |
ClinicalTrials.gov (NCT04606264) Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data
|
| 190 |
ClinicalTrials.gov (NCT00290823) Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
|
| 191 |
ClinicalTrials.gov (NCT01734928) Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
|
| 192 |
ClinicalTrials.gov (NCT03440411) Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
|
| 193 |
ClinicalTrials.gov (NCT01023308) Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
|
| 194 |
ClinicalTrials.gov (NCT03308084) Use of Local Intraoperative Steroid in MIS TLIF
|
| 195 |
ClinicalTrials.gov (NCT03252457) Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
|
| 196 |
ClinicalTrials.gov (NCT03643666) Intraperitoneal Dexamethasone vs Dexamethasone Plus Magnesium Sulphate for Pain Relief in Laparoscopic Cholecystectomy
|
| 197 |
ClinicalTrials.gov (NCT02102789) A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
|
| 198 |
ClinicalTrials.gov (NCT05564286) Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
|
| 199 |
ClinicalTrials.gov (NCT06216158) Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
|
| 200 |
ClinicalTrials.gov (NCT03839940) Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
|
| 201 |
ClinicalTrials.gov (NCT03110562) Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
|
| 202 |
ClinicalTrials.gov (NCT05028348) A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
|
| 203 |
ClinicalTrials.gov (NCT01474915) Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
|
| 204 |
ClinicalTrials.gov (NCT04155008) Nutrition and Pharmacological Algorithm for Oncology Patients Study
|
| 205 |
ClinicalTrials.gov (NCT04123873) Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty
|
| 206 |
ClinicalTrials.gov (NCT02690922) Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients
|
| 207 |
ClinicalTrials.gov (NCT02635828) Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis
|
| 208 |
ClinicalTrials.gov (NCT05491304) Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
|
| 209 |
ClinicalTrials.gov (NCT03467750) Effect of Ketorolac on Post Adenotonsillectomy Pain
|
| 210 |
ClinicalTrials.gov (NCT05721027) Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.
|
| 211 |
ClinicalTrials.gov (NCT02763059) Comparison Between Dexamethasone and Ibuprofen on Pain Prevention and Control Following Surgical Implant Placement
|
| 212 |
ClinicalTrials.gov (NCT03005496) The Effect of Zinc, -carotene, and Vitamin D3 in Preterm Delivery Through Placental MyD88, TRIF, NFkB, and IL-1
|
| 213 |
ClinicalTrials.gov (NCT02739035) MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty
|
| 214 |
ClinicalTrials.gov (NCT03901768) Effects of Combined Topical and Systemic Steroid Administrations on Better Early Postoperative Pain Management in Total Knee Arthroplasty
|
| 215 |
ClinicalTrials.gov (NCT03998982) Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP
|
| 216 |
ClinicalTrials.gov (NCT03057015) Addition of Clonidine to Ropivacaine in Adductor Canal Block
|
| 217 |
ClinicalTrials.gov (NCT05716945) The OPTIMISE Study
|
| 218 |
ClinicalTrials.gov (NCT02989597) Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients
|
| 219 |
ClinicalTrials.gov (NCT04751175) Management of Pain in Lumbar Arthrodesis
|
| 220 |
ClinicalTrials.gov (NCT02873806) Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents
|
| 221 |
FDA Drug Development and Drug Interactions
|
|
|
|
|
|
|
